| Literature DB >> 30849441 |
Martin Vojtek1, Maria P M Marques2, Isabel M P L V O Ferreira3, Hélder Mota-Filipe4, Carmen Diniz5.
Abstract
Treatment of triple-negative breast carcinoma (TNBC) remains an unmet medical need with no targeted therapy available to date. Accounting for 10-30% of all human breast cancer tumors, this mammary carcinoma subtype has a particularly poor prognosis owing to its high metastatic potential, aggressive biology and limited pharmacological treatment options. Platinum chemotherapeutics are the mainstay therapy in patients with TNBC but their clinical use is limited by severe toxicity and acquired resistance. Palladium-based complexes are appealing alternative metal-based drugs because of significant similarities regarding structure and coordination chemistry with the platinum agents. This review summarizes the knowledge gathered so far on 121 Pd(II) complexes, emphasizing their anticancer activity and putative pharmacological targets toward TNBC.Entities:
Mesh：
Substances：
Year: 2019 PMID： 30849441 DOI： 10.1016/j.drudis.2019.02.012
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851